ClinicalTrialsFinder
RecruitingNCT06468774

Intestinal Ischemia Biomarker in Patients With Chronic Mesenteric Ischemia

Intestinal Ischemia Biomarker and Quality of Life of the Patients With Chronic Mesenteric Ischemia and Median Arcuate Ligament Syndrome

Sponsor

Oslo University Hospital

Enrollment

180 participants

Start Date

Jun 10, 2024

Study Type

OBSERVATIONAL

Conditions

Crohn DiseaseCholelithiasisChronic Mesenteric IschemiaMedian Arcuate Ligament Syndrome

Summary

Plasma Alpha glutathione S transferase (Alpha GST) has been previously demonstrated to be raised in patients with chronic mesenteric ischemia (CMI) caused by atherosclerosis and in patients with median arcuate ligament syndrome (MALS). Raised plasma level of Alpha GST has been demonstrated to decrease or normalize after surgical treatment of patients with CMI and MALS as compared with healthy individuals. This study compares the plasma Alpha GST in patients with CMI and MALS with those with 1-Morbus Crohn, 2-Gallstone disease, and age-matched healthy individuals. Besides, changes in the health-related quality of life (QoL) will be investigated in the study individuals.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is looking for blood biomarkers (specific proteins or markers in the blood) that can help diagnose intestinal ischemia — a condition where the intestines do not get enough blood supply. It compares levels in patients with vascular disease to healthy volunteers. **You may be eligible if...** - You are over 18 years old and have given written consent - You have been diagnosed with chronic mesenteric ischemia (CMI) or median arcuate ligament syndrome (MALS) and are scheduled for treatment - OR you are a healthy blood donor aged around 45 or 70 without vascular disease - OR you have Crohn's disease under routine monitoring - OR you have gallstones and are scheduled for gallbladder removal **You may NOT be eligible if...** - You are under 18 years old - You have not provided written consent Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

PROCEDURELaparoscopic surgery

The patients in the MALS group will be treated through transperitoneal ventral approach for the laparoscopic release of the celiac artery. Median arcuate ligament and any muscle or nerve tissue crossing the cranial surface of the celiac artery will be divided to release the celiac artery from compression. In the patients with CMI open antegrade or retrograde bypass to celiac artery or superior mesenteric artery or both will be performed. For operative treatment will be performed in general anaethesia whereas the endovacular treatment with PTA with stent for CMI will be performed in local anaethesia.

Locations(1)

Department of vascular surgery, Oslo University Hospital

Oslo, Oslo, Norway

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06468774

Related Trials

Standardized Microbiota Transplant Therapy in Crohn's Disease

NCT066315862 locations

A Smartphone Application for Added Psychological Wellbeing in Crohn's Disease

NCT062212544 locations

IBD-Sleep: A Pilot Study Looking at Changes in Sleep Timing and IBD Symptoms

NCT060946081 location

Predictors of Prognosis in IBD Patients

NCT056530111 location

Seattle Spatial Transcriptomic Research in Inflammatory Bowel Disease Evaluation (STRIDE)

NCT063151791 location